ESR1 and breast cancer: Comparison of CTCs in situ before cell culture with the CTC line indicates that it mirrors the situation in ER+ breast cancer patients and therefore provides novel insights into the biology and drug response of patient‐derived CTCs in the most common breast cancer subtype.